Multicentric study to evaluate potential vessel damage in patients suffering from Thalidomide brth defect (Contergan)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030210

Enrollment

876

Registered

2022-09-15

Start date

2023-05-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q27

Interventions

Group 1: MRI in patients with birth defect caused by Thalidomid Group 2: healthy volunteers

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients, registered by Contergan foundation with an underlying malfunction or disability caused by Thalidomide; healthy volunteers

Exclusion criteria

Exclusion criteria: known contraindication for assessment by MRI; pregnancy; Body weight higher than 150 kg; Claustrophobia

Design outcomes

Primary

Measure	Time frame
Registration of frequency and kind of Organ- and Vesselanomaly, as well as assessment of diameter of the vessels in patiente suffering from Thalidomide induced deficiencies.	—

Secondary

Measure	Time frame
MRI assessment of cardial anomaly; US assessment of arteriosclerotic changes; Assessment of severitiy of Hypertonia; blood/urine assessment; Diameter and alteration of vessels in comparison to healthy volunteers.	—

Countries

Germany

Contacts

Public ContactDavid Maintz

Institut für Diagnostische und Interventionelle RadiologieUniversitätsklinikum Köln

David.Maintz@uk-koeln.de0221 478-82035

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026